UnitedHealth shares jump the most in 5 years after Buffett’s new stake is revealed

UnitedHealth shares jump the most in 5 years after Buffett’s new stake is revealed


UnitedHealth Group Inc. signage on the floor of the New York Stock Exchange on April 21, 2025.

Michael Nagle | Bloomberg | Getty Images

Stock Chart IconStock chart icon

hide content

UnitedHealth Friday

Shares of UnitedHealth were down nearly 50% for 2025 through Thursday’s close before Buffett’s filing. The largest private health insurer has become the face of public blowback in this country against the rising costs of health care. UnitedHealth is currently facing a Justice Department investigation into its Medicare billing practices.

In May, the company pulled its annual earnings outlook and CEO Andrew Witty stepped down. Last month, UnitedHealth gave a new 2025 outlook that was well short of Wall Street estimates, hitting the stock further.

“The move by Berkshire represents a big vote of confidence in UNH and likely could provide a near-term trading floor for most of the MCO space and, given Berkshire’s investment track record, could serve as a near-term bottom and rallying point for other investors that the space is safe to invest in again,” George Hill, a health care analyst at Deutsche Bank, said in a note to clients.

Don’t miss these insights from CNBC PRO



Source

Pfizer tops estimates, raises profit guidance even as sales fall
Health

Pfizer tops estimates, raises profit guidance even as sales fall

Smith Collection | Archive Photos | Getty Images Pfizer on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit guidance, as cost cuts helped to outweigh declining sales for the period. The pharmaceutical giant now expects its full-year adjusted profit to come in between $3 and $3.15 per share, up […]

Read More
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
Health

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech

A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025. Mike Blake | Reuters Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is […]

Read More
Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More